Product Code: PHM025D
REPORT HIGHLIGHTS
The global systemic antibiotics market should reach nearly $44.7 billion in 2020 from nearly $40.6 billion in 2015 at a compound annual growth rate (CAGR) of 2.0% from 2015 to 2020.
This report provides:
- An overview of the global markets and related technologies for antibiotics.
- Analyses of global market trends, with data from 2014, 2015, and projections of compound annual growth rates (CAGRs) through 2020.
- Breakdowns of the market by human application and veterinary application
- A look at major market trends and the factors driving or inhibiting the growth of the global pharmaceutical antibiotics market and its various submarkets
- Profiles of key players in the market and analysis of their core competencies and market shares
- Detailed coverage of
- Beta-lactams.
- Penicillin.
- Cephalosporins.
- Carbapenems.
- Fluoroquinolones.
- Second generation.
- Third generation.
- Others.
- Macrolides.
- Tetracycline.
- Other antibiotic classes.
SCOPE OF REPORT
This research report categorizes the systemic antibiotics market into the following segments:
Antibiotics market (human application) by product:
- Beta-lactams.
- Penicillin.
- Cephalosporins.
- Carbapenems.
- Fluoroquinolones.
- Second generation.
- Third generation.
- Others.
- Macrolides.
- Tetracycline.
- Other antibiotic classes.
- Antibiotics market by application:
- Human applications.
- Veterinary applications.
Launch of any new antibiotics during the forecast period has not been accounted in the market.
ANALYST'S CREDENTIALS
Neha Maliwal, a graduate in biotechnology and a postgraduate in marketing and biotechnology from the University of Pune (India), is the author of this study and numerous others, including the analyses of related markets such as radiopharmaceuticals, healthcare analytics, radiotherapy devices, healthcare business process outsourcing (BPO), and biotechnology instrumentation.
Table of Contents
CHAPTER 1 - INTRODUCTION
- STUDY GOALS AND OBJECTIVES
- REASONS FOR DOING THE STUDY
- SCOPE OF REPORT
- INTENDED AUDIENCE
- RESEARCH METHODOLOGY
- ANALYST'S CREDENTIALS
- RELATED BCC RESEARCH REPORTS
- BCC RESEARCH WEBSITE
- DISCLAIMER
CHAPTER 2 - EXECUTIVE SUMMARY
- SUMMARY TABLE: GLOBAL ANTIBIOTICS MARKET BY CLASS, THROUGH 2020 ($ MILLIONS)
- SUMMARY FIGURE: GLOBAL ANTIBIOTICS MARKET BY CLASS, 2015 AND 2020 ($ MILLIONS)
CHAPTER 3 - MARKET OVERVIEW
- INTRODUCTION
- BACTERIA
- TABLE 1: DIFFERENCES BETWEEN GRAM-NEGATIVE AND GRAM-POSITIVE BACTERIA
- GRAM-POSITIVE BACTERIA
- GRAM-NEGATIVE BACTERIA
- Mycobacterium
- TABLE 2: CLASSIFICATION OF BACTERIA BY SHAPE
- BACTERIAL INFECTIONS
- RESPIRATORY TRACT INFECTIONS
- Upper Respiratory Tract Infection
- TABLE 3: PRINCIPLES FOR JUDICIAL USE OF ANTIBIOTICS
- TABLE 4: INCIDENCE OF UPPER RESPIRATORY TRACT INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%)
- Lower Respiratory Tract Infection
- PNEUMONIA
- TABLE 5 COMMON CAUSATIVE MICROBES OF COMMUNITY AND HOSPITAL-ACQUIRED PNEUMONIA
- Community-acquired Pneumonia
- Hospital-acquired Pneumonia
- TABLE 6: PREFERRED PHARMACOTHERAPY FOR MICROORGANISMS CAUSING BACTERIAL PNEUMONIA
- TABLE 7: INCIDENCE OF COMMUNITY-ACQUIRED PNEUMONIA BY COUNTRY, 2010 (NUMBER/%)
- TUBERCULOSIS
- URINARY TRACT INFECTIONS (UTI)
- TABLE 8: INCIDENCE OF URINARY TRACT INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%)
- SKIN AND SKIN STRUCTURE INFECTIONS
- TABLE 9: INCIDENCE OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%)
- Cellulitis and Erysipelas
- Folliculitis
- Impetigo and Ecthyma
- Abscesses
- Carbuncles and Furuncles
- GYNECOLOGICAL INFECTIONS
- TABLE 10: INCIDENCE OF BACTERIAL VAGINOSIS INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%)
- DEFINITION OF ANTIBIOTIC
- CLASSIFICATION OF ANTIBIOTICS
- FIGURE 1: CLASSIFICATION OF ANTIBIOTICS
- HISTORY OF ANTIBIOTICS AND CURRENT STATUS
- PRE-ANTIBIOTIC ERA
- ANTIBIOTIC ERA
- TABLE 11: U.S. LIFE EXPECTANCY AT BIRTH, 1920-2013 (YEARS)
- TABLE 12: ANTIBIOTICS: YEAR OF INTRODUCTION, MODE OF ACTION AND TARGET SPECIES
- ANTIBIOTIC-RESISTANT BACTERIA
- MECHANISM OF RESISTANCE
- TABLE 13: ANTIBIOTICS: MODE OF ACTION
- Mechanisms of Antimicrobial Resistance
- TABLE 14: ESTIMATED DEATHS PER YEAR CAUSED BY AMR BY REGION, 2050 (NUMBER)
- Methods for the Dissemination of Antimicrobial Resistance Genes
- Resistance to B-Lactam Antibiotics
- Tetracycline Resistance
- Chloramphenicol Resistance
- Aminoglycoside Resistance
- Quinolone Resistance
- Macrolide, Lincosamide, and Streptogramin (MLS) Resistance
- Glycopeptide Resistance
- Sulfonamides and Trimethoprim Resistance
- Multidrug Resistance
- TABLE 15: TYPES OF ANTIBIOTICS AND METHODS OF RESISTANCE
- TABLE 16: CURRENT AND EMERGING ANTIBIOTIC-RESISTANT BACTERIA
- EMERGENCE OF POST-ANTIBIOTIC ERA
- TABLE 17: BIOCHEMICAL MECHANISM OF ANTIBIOTIC RESISTANCE
- FIGURE 2: CDC LIST OF HIGHLY CONCERNING BACTERIA, ACCORDING TO THREAT LEVEL
- TABLE 18: ADDITIONAL COST AND LENGTH OF STAY DUE TO ANTIBIOTIC-RESISTANT BACTERIA BY REGION
- Limitation of Antibiotics
- Some Antibiotics are Active against Only Certain Kinds of Bacteria
- Some Bacteria are Virulent and Can Kill Quickly
- Some Bacteria Grow in Biofilms that cannot be Easily Penetrated by Antibiotics
- DRIVERS RESTRAINTS AND OPPORTUNITIES
- DRIVERS
- Growth of the Global Pharmaceutical Market Driven by Antibiotics
- Aging Population Propels the Growth of the Antibiotics Market
- FIGURE 3: INCREASE IN AGING POPULATION, 2011 AND 2050
- Public-Private Partnerships Encourage Antibiotic Development
- Increasing Prevalence of Hospital-Acquired Infections Triggers Market Growth
- RESTRAINTS
- Antibiotic Resistance
- Declining R&D Investment Poses Long-Term Barrier to Market Growth
- Genericization of Antibiotics Restrains Market Growth
- OPPORTUNITIES
- Market Expansion into Emerging Countries
- Multidrug-Resistant Pathogens Provide an Opportunity to Develop Novel Antibacterial Agents
- BURNING ISSUE
- New Antibiotic Discovered From Soil
- MARKET SHARES OF KEY COMPANIES
- FIGURE 4: GLOBAL MARKET SHARES FOR ANTIBIOTIC COMPANIES, 2014 (%)
- VALUE CHAIN OF ANTIBIOTICS
- CHINA IS A BECOMING A CENTER FOR MICROBIAL THREATS
- REGULATORY ISSUES
- FDA AND INTERNATIONAL REGULATORY AGENCIES
- RECENT REGULATORY REFORMS
- KETEK CASE STUDY
- KEY TRENDS AFFECTING THE MARKET
- NEVER EVENTS
- Impact on the Use of Antibiotics
- FUNDING FOR NEW ANTIBIOTICS
- United States
- Infectious Diseases Society of America
- NIH Funding
- Public-Private Partnerships
- Europe
- Innovative Medicines Initiative
- EMERGING DRUGS WITH NOVEL MECHANISMS OF ACTION
- PharmaSea Project
- Combination of Different Antibiotics
- Others
CHAPTER 4 - ANTIBIOTIC RESEARCH AND DEVELOPMENT
- REASONS FOR LACK OF INNOVATION IN ANTIBIOTIC RESEARCH
- FIGURE 5: REASONS FOR LACK OF INNOVATION IN ANTIBIOTIC RESEARCH
- LOW RETURN ON INVESTMENT
- STRICT REGULATORY ENVIRONMENT
- SCIENTIFIC CHALLENGES
- STRATEGIES TO PROMOTE ANTIBIOTIC RESEARCH
- FIGURE 6: STRATEGIES TO PROMOTE ANTIBIOTIC RESEARCH
- PUSH STRATEGIES
- Increasing Access to Research
- Increasing the Number of Scientific Personnel
- Direct Funding of Research
- Translational Research
- Tax Incentives
- Product Development Partnerships
- PULL STRATEGIES
- Monetary Awards
- Advance Market Commitments
- Legal and Regulatory Initiatives
- Clinical Trials
- Accelerated Regulatory Review
- Intellectual Property Rights Strategies
- Increasing the Term of IP Protection and Data Exclusivity
- Wildcard Patent Extension
- Patent Buyouts
- Pricing and Reimbursement
- Other Legal/Regulatory Strategies
- COMBINED PULL AND PUSH INCENTIVES
- ORPHAN DRUG STATUS
- TABLE 19: COMPARISON OF U.S. AND EU ORPHAN DRUG LEGISLATION AND PROCESS
- Delinkage of Antibiotics
- TABLE 20: LIST OF DELINKAGE MODELS
- TABLE 21: LIST OF HYBRID MODELS
CHAPTER 5 - ANTIBIOTICS MARKET BY TYPE
- MARKET SIZE ESTIMATION
- MARKET SHARE ESTIMATION
- GLOBAL ANTIBIOTICS MARKET BY CLASS
- TABLE 22: GLOBAL ANTIBIOTICS MARKET BY CLASS, THROUGH 2020 ($ MILLIONS)
- TABLE 23: GLOBAL ANTIBIOTICS MARKET BY REGION, THROUGH 2020 ($ MILLIONS)
- FIGURE 7: ANTIBIOTICS BY CLASS
- BETA-LACTAM ANTIBIOTICS
- TABLE 24: GLOBAL MARKET FOR BETA-LACTAM ANTIBIOTICS BY TYPE, THROUGH 2020 ($ MILLIONS)
- TABLE 25: GLOBAL MARKET FOR BETA-LACTAM ANTIBIOTICS BY REGION, THROUGH 2020 ($ MILLIONS)
- Extended Spectrum Beta-Lactamase
- Metallo-Beta-Lactamases
- FIGURE 8: TYPES OF BETA-LACTAM ANTIBIOTICS
- Penicillins
- TABLE 26: GLOBAL MARKET FOR PENICILLIN BY REGION, THROUGH 2020 ($ MILLIONS)
- Types of Penicillin
- TABLE 27: TYPES OF PENICILLIN BY BRAND NAME AND APPROVAL DATE
- Cephalosporins
- Side Effects
- TABLE 28: GLOBAL MARKET FOR CEPHALOSPORIN BY REGION, THROUGH 2020 ($ MILLIONS)
- Teflaro Driving the Cephalosporin Market
- Generations of Cephalosporins
- TABLE 29: GENERATIONS OF CEPHALOSPORIN
- First-Generation Cephalosporins
- TABLE 30: LIST OF FIRST-GENERATION CEPHALOSPORINS
- Second-Generation Cephalosporins
- TABLE 31: LIST OF SECOND-GENERATION CEPHALOSPORINS
- Third-Generation Cephalosporins
- Antipseudomonal Cephalosporins
- TABLE 32: LIST OF THIRD-GENERATION CEPHALOSPORINS
- Fourth-Generation Cephalosporins
- TABLE 33: LIST OF FOURTH-GENERATION CEPHALOSPORINS
- Fifth-Generation Cephalosporins
- TABLE 34: LIST OF FIFTH-GENERATION CEPHALOSPORINS
- Carbapenems
- TABLE 35: GLOBAL MARKET FOR CARBAPENEM BY REGION, THROUGH 2020 ($ MILLIONS)
- TABLE 36: TYPES OF CARBAPENEMS
- QUINOLONES AND FLUOROQUINOLONES
- TABLE 37: DEVELOPMENT HISTORY OF FLUOROQUINOLONES
- TABLE 38: GLOBAL MARKET FOR FLUOROQUINOLONES BY GENERATION, THROUGH 2020 ($ MILLIONS)
- TABLE 39: GLOBAL MARKET FOR FLUOROQUINOLONES BY REGION, THROUGH 2020 ($ MILLIONS)
- Generations of Quinolones
- First-Generation Quinolones
- Second-Generation Fluoroquinolones
- TABLE 40: GLOBAL MARKET FOR SECOND-GENERATION FLUOROQUINOLONES BY REGION, THROUGH 2020 ($ MILLIONS)
- Third-Generation Fluoroquinolones
- TABLE 41: GLOBAL MARKET FOR THIRD-GENERATION FLUOROQUINOLONES BY REGION, THROUGH 2020 ($ MILLIONS)
- Levofloxacin: A Major Driver of the Market for Third-Generation Fluoroquinolones
- Fourth-Generation Fluoroquinolones
- TABLE 42: GLOBAL MARKET FOR OTHER QUINOLONES BY REGION, THROUGH 2020 ($ MILLIONS)
- TABLE 43: TYPES OF QUINOLONES
- TETRACYCLINE
- TABLE 44: GLOBAL MARKET FOR TETRACYCLINE BY REGION, THROUGH 2020 ($ MILLIONS)
- TABLE 45: TYPES OF TETRACYCLINE
- MACROLIDES
- TABLE 46: GLOBAL MARKET FOR MACROLIDE BY REGION, THROUGH 2020 ($ MILLIONS)
- Ketolides
- Ketek
- TABLE 47: TYPES OF MACROLIDES/KETOLIDES
- OTHER ANTIBIOTICS
- Pseudomonas Aeruginosa
- TABLE 48: GLOBAL MARKET FOR OTHER ANTIBIOTICS BY REGION, THROUGH 2020 ($ MILLIONS)
CHAPTER 6 - VETERINARY ANTIBIOTICS MARKET
- INTRODUCTION
- TABLE 49: DIFFERENCES BETWEEN ANTIBIOTIC USAGE IN ANIMALS AND HUMANS
- TABLE 50: GLOBAL MARKET FOR VETERINARY ANTIBIOTICS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
- VETERINARY APPLICATIONS
- FEED APPLICATION
- FDA to Phase out Antibiotics from Food Production
- THERAPEUTIC APPLICATIONS
- TABLE 51: GLOBAL MARKET FOR VETERINARY THERAPEUTIC ANTIBIOTICS BY TYPE, THROUGH 2020 ($ MILLIONS)
- TABLE 52: GLOBAL MARKET FOR VETERINARY THERAPEUTIC ANTIBIOTICS BY ANIMAL TYPE, THROUGH 2020 ($ MILLIONS)
- OTHER APPLICATIONS
CHAPTER 7 - COMPANY PROFILES
- ASTRAZENECA
- FINANCIALS
- TABLE 53: ASTRAZENECA REVENUES AND R &D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
- DEVELOPMENTS
- TABLE 54: ASTRAZENECA DEVELOPMENTS
- BAYER HEALTHCARE AG
- FINANCIALS
- TABLE 55: BAYER REVENUES AND R &D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
- DEVELOPMENTS
- CUBIST PHARMACEUTICALS
- DEVELOPMENTS
- TABLE 56: CUBIST PHARMACEUTICAL DEVELOPMENTS
- GLAXOSMITHKLINE
- FINANCIALS
- TABLE 57: GSK REVENUES AND R & D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
- DEVELOPMENTS
- TABLE 58 GSK DEVELOPMENTS
- JOHNSON & JOHNSON
- FINANCIALS
- TABLE 59: JOHNSON & JOHNSON REVENUES AND R &D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
- DEVELOPMENTS
- TABLE 60: JOHNSON & JOHNSON DEVELOPMENTS
- MERCK & CO.
- FINANCIALS
- TABLE 61: MERCK & CO. REVENUES AND R &D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
- DEVELOPMENTS
- TABLE 62: MERCK & CO.DEVELOPMENTS
- PFIZER
- FINANCIALS
- TABLE 63: PFIZER REVENUES AND R &D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
- DEVELOPMENTS
- TABLE 64: PFIZER DEVELOPMENTS
- RECENT MERGERS AND ACQUISITIONS
- TABLE 65: LIST OF OTHER COMPANIES IN THE ANTIBIOTICS MARKET
CHAPTER 8 - CLINICAL TRIALS ON ANTIBIOTICS
- FIGURE 9: ANTIBIOTICS IN PHASES I-III CLINICAL TRIALS, 2015 (%)
- TABLE 66: ANTIBIOTIC COMPOUNDS IN PHASE III CLINICAL TRIALS, 2015
- ANTIBIOTICS IN PHASE II CLINICAL TRIALS
- TABLE 67: ANTIBIOTIC COMPOUNDS IN PHASE II CLINICAL TRIALS, 2015
- ANTIBIOTICS IN PHASE I CLINICAL TRIALS
- TABLE 68: ANTIBIOTIC COMPOUNDS IN PHASE I CLINICAL TRIALS, 2015
- TABLE 69: NATURAL PRODUCTS IN CLINICAL TRIALS FOR ANTIBIOTIC ACTIVITY THAT REPRESENT NEW CHEMICAL CLASSES, 2015
CHAPTER 9 - OVERVIEW OF BACTERIA TYPES
- DISEASE ORGANISMS, DIAGNOSTICS, CLINICAL MANIFESTATIONS AND TREATMENTS
- TABLE 70: LIST OF GRAM-POSITIVE BACTERIA
- TABLE 71: LIST OF GRAM-NEGATIVE BACTERIA
- TABLE 72: LIST OF GRAM-NEGATIVE COCCI
- TABLE 73: LIST OF GRAM-NEGATIVE RODS RELATED TO RESPIRATORY TRACT INFECTIONS
- TABLE 74: LIST OF GRAM-NEGATIVE RODS RELATED TO THE ENTERIC TRACT
- TABLE 75: LIST OF GRAM-NEGATIVE SPIROCHETES
- TABLE 76: LIST OF GRAM-NEGATIVE OBLIGATE INTRACELLULAR PARASITES
- TABLE 77: LIST OF MISCELLANEOUS BACTERIA
CHAPTER 10 - LIST OF ACRONYMS
LIST OF TABLES
- SUMMARY TABLE: GLOBAL ANTIBIOTICS MARKET BY CLASS, THROUGH 2020 ($ MILLIONS)
- TABLE 1: DIFFERENCES BETWEEN GRAM-NEGATIVE AND GRAM-POSITIVE BACTERIA
- TABLE 2: CLASSIFICATION OF BACTERIA BY SHAPE
- TABLE 3: PRINCIPLES FOR JUDICIAL USE OF ANTIBIOTICS
- TABLE 4: INCIDENCE OF UPPER RESPIRATORY TRACT INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%)
- TABLE 5: COMMON CAUSATIVE MICROBES OF COMMUNITY AND HOSPITAL-ACQUIRED PNEUMONIA
- TABLE 6: PREFERRED PHARMACOTHERAPY FOR MICROORGANISMS CAUSING BACTERIAL PNEUMONIA
- TABLE 7: INCIDENCE OF COMMUNITY-ACQUIRED PNEUMONIA BY COUNTRY, 2010 (NUMBER/%)
- TABLE 8: INCIDENCE OF URINARY TRACT INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%)
- TABLE 9: INCIDENCE OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%)
- TABLE 10: INCIDENCE OF BACTERIAL VAGINOSIS INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%)
- TABLE 11: U.S. LIFE EXPECTANCY AT BIRTH, 1920-2013 (YEARS)
- TABLE 12: ANTIBIOTICS: YEAR OF INTRODUCTION, MODE OF ACTION AND TARGET SPECIES
- TABLE 13: ANTIBIOTICS: MODE OF ACTION
- TABLE 14: ESTIMATED DEATHS PER YEAR CAUSED BY AMR BY REGION, 2050 (NUMBER)
- TABLE 15: TYPES OF ANTIBIOTICS AND METHODS OF RESISTANCE
- TABLE 16: CURRENT AND EMERGING ANTIBIOTIC-RESISTANT BACTERIA
- TABLE 17: BIOCHEMICAL MECHANISM OF ANTIBIOTIC RESISTANCE
- TABLE 18: ADDITIONAL COST AND LENGTH OF STAY DUE TO ANTIBIOTIC-RESISTANT BACTERIA BY REGION
- TABLE 19: COMPARISON OF U.S. AND EU ORPHAN DRUG LEGISLATION AND PROCESS
- TABLE 20: LIST OF DELINKAGE MODELS
- TABLE 21: LIST OF HYBRID MODELS
- TABLE 22: GLOBAL ANTIBIOTICS MARKET BY CLASS, THROUGH 2020 ($ MILLIONS)
- TABLE 23: GLOBAL ANTIBIOTICS MARKET BY REGION, THROUGH 2020 ($ MILLIONS)
- TABLE 24: GLOBAL MARKET FOR BETA-LACTAM ANTIBIOTICS BY TYPE, THROUGH 2020 ($ MILLIONS)
- TABLE 25: GLOBAL MARKET FOR BETA-LACTAM ANTIBIOTICS BY REGION, THROUGH 2020 ($ MILLIONS)
- TABLE 26: GLOBAL MARKET FOR PENICILLIN BY REGION, THROUGH 2020 ($ MILLIONS)
- TABLE 27: TYPES OF PENICILLIN BY BRAND NAME AND APPROVAL DATE
- TABLE 28: GLOBAL MARKET FOR CEPHALOSPORIN BY REGION, THROUGH 2020 ($ MILLIONS)
- TABLE 29: GENERATIONS OF CEPHALOSPORIN
- TABLE 30: LIST OF FIRST-GENERATION CEPHALOSPORINS
- TABLE 31: LIST OF SECOND-GENERATION CEPHALOSPORINS
- TABLE 32: LIST OF THIRD-GENERATION CEPHALOSPORINS
- TABLE 33: LIST OF FOURTH-GENERATION CEPHALOSPORINS
- TABLE 34: LIST OF FIFTH-GENERATION CEPHALOSPORINS
- TABLE 35: GLOBAL MARKET FOR CARBAPENEM BY REGION, THROUGH 2020 ($ MILLIONS)
- TABLE 36: TYPES OF CARBAPENEMS
- TABLE 37: DEVELOPMENT HISTORY OF FLUOROQUINOLONES
- TABLE 38: GLOBAL MARKET FOR FLUOROQUINOLONES BY GENERATION, THROUGH 2020 ($ MILLIONS)
- TABLE 39: GLOBAL MARKET FOR FLUOROQUINOLONES BY REGION, THROUGH 2020 ($ MILLIONS)
- TABLE 40: GLOBAL MARKET FOR SECOND-GENERATION FLUOROQUINOLONES BY REGION, THROUGH 2020 ($ MILLIONS)
- TABLE 41: GLOBAL MARKET FOR THIRD-GENERATION FLUOROQUINOLONES BY REGION, THROUGH 2020 ($ MILLIONS)
- TABLE 42: GLOBAL MARKET FOR OTHER QUINOLONES BY REGION, THROUGH 2020 ($ MILLIONS)
- TABLE 43: TYPES OF QUINOLONES
- TABLE 44: GLOBAL MARKET FOR TETRACYCLINE BY REGION, THROUGH 2020 ($ MILLIONS)
- TABLE 45: TYPES OF TETRACYCLINE
- TABLE 46: GLOBAL MARKET FOR MACROLIDE BY REGION, THROUGH 2020 ($ MILLIONS)
- TABLE 47: TYPES OF MACROLIDES/KETOLIDES
- TABLE 48: GLOBAL MARKET FOR OTHER ANTIBIOTICS BY REGION, THROUGH 2020 ($ MILLIONS)
- TABLE 49: DIFFERENCES BETWEEN ANTIBIOTIC USAGE IN ANIMALS AND HUMANS
- TABLE 50: GLOBAL MARKET FOR VETERINARY ANTIBIOTICS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
- TABLE 51: GLOBAL MARKET FOR VETERINARY THERAPEUTIC ANTIBIOTICS BY TYPE, THROUGH 2020 ($ MILLIONS)
- TABLE 52: GLOBAL MARKET FOR VETERINARY THERAPEUTIC ANTIBIOTICS BY ANIMAL TYPE, THROUGH 2020 ($ MILLIONS)
- TABLE 53: ASTRAZENECA REVENUES AND R &D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
- TABLE 54: ASTRAZENECA DEVELOPMENTS
- TABLE 55: BAYER REVENUES AND R &D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
- TABLE 56: CUBIST PHARMACEUTICAL DEVELOPMENTS
- TABLE 57: GSK REVENUES AND R & D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
- TABLE 58: GSK DEVELOPMENTS
- TABLE 59: JOHNSON & JOHNSON REVENUES AND R &D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
- TABLE 60: JOHNSON & JOHNSON DEVELOPMENTS
- TABLE 61: MERCK & CO. REVENUES AND R &D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
- TABLE 62: MERCK & CO.DEVELOPMENTS
- TABLE 63: PFIZER REVENUES AND R &D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
- TABLE 64: PFIZER DEVELOPMENTS
- TABLE 65: LIST OF OTHER COMPANIES IN THE ANTIBIOTICS MARKET
- TABLE 66: ANTIBIOTIC COMPOUNDS IN PHASE III CLINICAL TRIALS, 2015
- TABLE 67: ANTIBIOTIC COMPOUNDS IN PHASE II CLINICAL TRIALS, 2015
- TABLE 68: ANTIBIOTIC COMPOUNDS IN PHASE I CLINICAL TRIALS, 2015
- TABLE 69: NATURAL PRODUCTS IN CLINICAL TRIALS FOR ANTIBIOTIC ACTIVITY THAT REPRESENT NEW CHEMICAL CLASSES, 2015
- TABLE 70: LIST OF GRAM-POSITIVE BACTERIA
- TABLE 71: LIST OF GRAM-NEGATIVE BACTERIA
- TABLE 72: LIST OF GRAM-NEGATIVE COCCI
- TABLE 73: LIST OF GRAM-NEGATIVE RODS RELATED TO RESPIRATORY TRACT INFECTIONS
- TABLE 74: LIST OF GRAM-NEGATIVE RODS RELATED TO THE ENTERIC TRACT
- TABLE 75: LIST OF GRAM-NEGATIVE SPIROCHETES
- TABLE 76: LIST OF GRAM-NEGATIVE OBLIGATE INTRACELLULAR PARASITES
- TABLE 77: LIST OF MISCELLANEOUS BACTERIA
LIST OF FIGURES
- SUMMARY FIGURE: GLOBAL ANTIBIOTICS MARKET BY CLASS, 2015 AND 2020 ($ MILLIONS)
- FIGURE 1: CLASSIFICATION OF ANTIBIOTICS
- FIGURE 2: CDC LIST OF HIGHLY CONCERNING BACTERIA, ACCORDING TO THREAT LEVEL
- FIGURE 3: INCREASE IN AGING POPULATION, 2011 AND 2050
- FIGURE 4: GLOBAL MARKET SHARES FOR ANTIBIOTIC COMPANIES, 2014 (%)
- FIGURE 5: REASONS FOR LACK OF INNOVATION IN ANTIBIOTIC RESEARCH
- FIGURE 6: STRATEGIES TO PROMOTE ANTIBIOTIC RESEARCH
- FIGURE 7: ANTIBIOTICS BY CLASS
- FIGURE 8: TYPES OF BETA-LACTAM ANTIBIOTICS
- FIGURE 9: ANTIBIOTICS IN PHASES I-III CLINICAL TRIALS, 2015 (%)
